EPN3 Antibody

What is EPN3 and what cellular functions does it perform?

EPN3 (Epsin 3) belongs to the epsin family of endocytic adapter proteins that also includes EPN1 and EPN2. It functions primarily in clathrin-mediated endocytosis, facilitating the internalization of cell surface receptors . Recent research has revealed that EPN3 plays significant roles beyond endocytosis, particularly in cancer progression. It has been identified as a direct target of the tumor suppressor p53 and is involved in regulating apoptotic pathways . EPN3 has a calculated molecular weight of approximately 68 kDa (632 amino acids) and is typically observed at 68-70 kDa in experimental conditions .

What are the typical applications of EPN3 antibodies in research?

EPN3 antibodies are utilized across multiple experimental platforms, with the most common applications being:

• Western Blotting (WB): For detecting and quantifying EPN3 protein expression

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative protein detection

• Immunohistochemistry (IHC): For visualizing EPN3 in tissue sections

• Immunofluorescence (IF): For subcellular localization studies

• Immunocytochemistry (ICC): For cellular expression analysis

• Flow Cytometry (FACS): For quantifying EPN3 expression in cell populations

These applications can be applied to various sample types, including cell lines (such as MCF-7, MCF-10A, A549, H1299) and tissue samples from multiple species (human, mouse, rat), making EPN3 antibodies versatile tools for comparative studies .

How should researchers select the appropriate EPN3 antibody for their specific experimental needs?

Selection of an EPN3 antibody should be guided by several experimental considerations:

Researchers should review validation data for the specific antibody and application before proceeding with experiments.

What are the optimal dilution ranges for different applications of EPN3 antibodies?

Optimal antibody dilutions vary by application type and specific antibody preparation. Based on available data:

It is strongly recommended that researchers perform titration experiments to determine optimal conditions for their specific samples and experimental setup. Sample-dependent variation is common, particularly across different tissue types or cell lines .

What common technical challenges occur when using EPN3 antibodies, and how can they be addressed?

Several technical issues may arise in EPN3 antibody applications:

• Background signal issues:

  • Use appropriate blocking solutions (5% BSA or milk)

  • Increase washing duration and frequency

  • Optimize antibody concentration through titration experiments

  • Consider using different detection systems for cleaner results

• Multiple bands in Western blots:

  • May represent post-translational modifications or cleavage products of EPN3

  • Include positive and negative controls to identify specific bands

  • Use cell lines with known EPN3 expression (MCF-10A, MCF-7) as reference

• Low signal strength:

  • Increase protein loading or antibody concentration

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use signal enhancement systems compatible with your detection method

  • Verify EPN3 expression levels in your experimental system

• Cross-reactivity:

  • Use antibodies validated for your species of interest

  • Include appropriate controls (knockdown/knockout samples where possible)

  • Perform pre-adsorption tests with immunizing peptides if available

What controls are essential when designing experiments with EPN3 antibodies?

Proper experimental controls are crucial for interpreting results with EPN3 antibodies:

• Positive controls: Use tissues or cell lines with confirmed EPN3 expression (MCF-10A, MCF-7, mouse/rat stomach tissue)

• Negative controls:

  • Include isotype controls to assess non-specific binding

  • Use EPN3 knockdown/knockout samples when available

  • Omit primary antibody in parallel samples to identify secondary antibody non-specific binding

• Loading controls: For Western blot, include housekeeping proteins (β-actin, GAPDH) to normalize expression levels

• Specificity controls: When possible, use multiple antibodies targeting different EPN3 epitopes to confirm observations

• Treatment controls: Include p53-modulating conditions, as EPN3 is a p53 target gene

How can EPN3 antibodies be utilized to investigate cancer progression mechanisms?

Recent research has established EPN3 as an important factor in cancer progression, particularly in epithelial-mesenchymal transition (EMT). EPN3 antibodies can be employed to:

• Track EMT markers in conjunction with EPN3:

  • Co-immunoprecipitation to identify EPN3 interaction partners during EMT

  • Co-staining with EMT markers (E-cadherin, N-cadherin, vimentin, ZEB1, snail) to correlate EPN3 expression with EMT status

  • Quantify changes in mesenchymal markers following EPN3 knockdown or overexpression

• Investigate EPN3's role in cellular migration and invasion:

  • Use EPN3 antibodies to monitor expression changes during migration/invasion assays

  • Correlate EPN3 levels with metastatic potential across cell lines and patient samples

  • Recent studies show that lowering EPN3 expression reduces metastatic and invasive capabilities in lung adenocarcinoma cells

• Study EPN3's relationship with the Wnt signaling pathway:

  • Monitor β-catenin levels in relation to EPN3 expression

  • Research has demonstrated that EPN3 knockdown affects key molecules in the Wnt pathway

• Analyze EPN3 in patient samples:

  • Use IHC with EPN3 antibodies to correlate expression with disease severity

  • Expression profile analysis has shown abnormal overexpression of EPN3 in lung adenocarcinoma patients, directly linked to disease severity

What methodologies can be employed to study the relationship between p53 and EPN3?

As EPN3 has been identified as a direct p53 target gene, several approaches can elucidate this relationship:

• Chromatin Immunoprecipitation (ChIP) assays:

  • Verify p53 binding to potential binding sites in the EPN3 locus

  • Research has identified at least three potential p53 binding sites (p53BS1, p53BS2, p53BS3) in the EPN3 gene

  • ChIP assays confirmed p53 binding to genomic regions including p53BS2 and p53BS3

• Reporter assays:

  • Construct reporter plasmids containing EPN3 promoter regions with p53 binding sites

  • Assess transcriptional activity in response to wild-type vs. mutant p53

  • Experiments can include base substitutions to identify critical binding sites

• Expression analysis following p53 modulation:

  • Monitor EPN3 expression after:

    • DNA damage agents that activate p53 (adriamycin, etoposide)

    • p53 knockdown/knockout

    • Ectopic expression of wild-type or mutant p53

  • Quantitative RT-PCR and Western blotting with EPN3 antibodies can track expression changes

• Analysis of EPN3 cleavage:

  • Western blot analysis using EPN3 antibodies can detect potential cleavage products

  • Investigate how p53 status affects EPN3 protein processing

How can EPN3 antibodies be used in the investigation of epithelial-mesenchymal transition in cancer cells?

EPN3 has been implicated in the EMT process, particularly in lung cancer. Researchers can investigate this relationship through:

• Comparative expression analysis:

  • Use Western blotting with EPN3 antibodies to compare expression across:

    • Epithelial vs. mesenchymal cell lines

    • Primary tumors vs. metastatic samples

    • Patient samples of varying disease stages

• Gene knockdown experiments:

  • Perform EPN3 knockdown in cancer cell lines (e.g., A549, H1299)

  • Use EPN3 antibodies to confirm knockdown efficiency

  • Measure changes in:

    • Mesenchymal markers (vimentin, N-cadherin)

    • Epithelial markers (E-cadherin)

    • EMT transcription factors (ZEB1, snail)

    • Wnt pathway molecules (β-catenin)

• Functional assays:

  • After confirming EPN3 modulation with antibodies, assess:

    • Cell migration (wound healing assays)

    • Invasion capacity (transwell assays)

    • Morphological changes

    • Metastatic potential in animal models

• Pathway analysis:

  • Use co-immunoprecipitation with EPN3 antibodies to identify interaction partners

  • Perform phosphorylation state analysis of signaling molecules

  • Correlate EPN3 expression with activation of EMT-related pathways

How should researchers interpret variable molecular weights observed for EPN3 in Western blots?

EPN3 has a calculated molecular weight of 68 kDa (632 amino acids), but experimental observations show it typically appears at 68-70 kDa . Several factors could explain variations:

• Post-translational modifications:

  • Phosphorylation, glycosylation, or ubiquitination can alter migration patterns

  • Different cell types may process EPN3 differently

• Protein cleavage:

  • EPN3 protein cleavage has been reported

  • Different antibodies targeting various epitopes may detect specific fragments

  • Consider the targeted region of your antibody when interpreting bands

• Splice variants:

  • Alternative splicing could generate EPN3 isoforms of different sizes

  • Verify known isoforms through database searches

• Technical variables:

  • Gel percentage, running conditions, and buffer systems affect migration

  • Use molecular weight markers and positive controls for accurate comparison

When unexpected bands appear, researchers should:

• Compare with positive control samples (MCF-10A, MCF-7 cells, stomach tissue)

• Consider using multiple antibodies targeting different EPN3 regions

• Perform validation with gene knockdown experiments

• Consult literature for known modifications or processing events

What statistical approaches are recommended for analyzing EPN3 expression data in cancer research?

When analyzing EPN3 expression data from antibody-based experiments:

• For comparing expression across groups:

  • Use t-tests for two-group comparisons (e.g., normal vs. tumor)

  • Apply ANOVA for multi-group comparisons (e.g., different cancer stages)

  • Consider non-parametric alternatives (Mann-Whitney, Kruskal-Wallis) if normality assumptions are violated

• For survival analysis:

  • Stratify patients by EPN3 expression levels

  • Perform Kaplan-Meier analysis with log-rank tests

  • Conduct Cox proportional hazards regression for multivariate analysis

• For correlation studies:

  • Use Pearson's or Spearman's correlation to assess relationships between EPN3 and:

    • EMT markers

    • Clinical parameters

    • Other molecular markers

• For experimental data:

  • Include biological replicates (n≥3) for robust statistical analysis

  • Present data with appropriate measures of central tendency and dispersion

  • Clearly define threshold values used to categorize expression levels

• For bioinformatic analyses:

  • Utilize public datasets to validate experimental findings

  • Consider machine learning approaches for pattern recognition

  • Perform pathway enrichment analysis to contextualize EPN3 function

What considerations are important when comparing EPN3 expression across different tissue types?

When comparing EPN3 expression in different tissues or cell types:

• Baseline expression levels:

  • EPN3 is differentially expressed across tissues

  • Establish baseline expression in normal tissues before making comparisons

  • Stomach tissue has been used as a positive control for EPN3 expression

• Antibody specificity across tissues:

  • Verify the antibody's cross-reactivity with your species of interest

  • Different tissue components may affect antibody binding or create background

  • Use appropriate blocking agents specific to the tissue type

• Normalization strategies:

  • For Western blots, normalize to housekeeping proteins appropriate for the tissue types

  • For IHC, consider using tissue microarrays for standardized conditions

  • For qPCR validation, select reference genes stable across the tissues being compared

• Technical considerations:

  • Tissue-specific fixation protocols may affect epitope accessibility

  • Antigen retrieval methods may need optimization for different tissues

  • Background autofluorescence varies by tissue type in IF applications

• Biological context:

  • Consider the role of the tissue microenvironment on EPN3 expression

  • Account for cell type heterogeneity within tissues

  • Interpret changes in context of tissue-specific function

How might EPN3 antibodies contribute to the development of cancer biomarkers or therapeutic targets?

Given EPN3's emerging role in cancer progression, antibody-based research could contribute to translational applications:

• Biomarker development:

  • EPN3 overexpression has been linked to disease severity in lung adenocarcinoma

  • EPN3 antibodies could be used to develop immunohistochemical scoring systems

  • Correlation of EPN3 with EMT markers may provide prognostic information

  • Develop multiplexed IHC panels including EPN3 and related proteins

• Therapeutic target validation:

  • Use EPN3 antibodies to monitor protein downregulation following experimental interventions

  • Assess effects of EPN3 inhibition on cancer hallmarks (migration, invasion, proliferation)

  • Recent research shows that lowering EPN3 expression reduces metastatic potential in lung cancer

• Companion diagnostics:

  • EPN3 expression may predict response to therapies targeting related pathways

  • Antibody-based assays could identify patients likely to benefit from specific treatments

  • Monitor treatment efficacy through changes in EPN3 expression or localization

Research investigating these translational applications should include rigorous validation across multiple patient cohorts and experimental models.